Skip to content

EV / sales at other companies

AbbVie logo
AbbVieABBV
7.5×+1.0×
Solesence, Inc. Common Stock logo
Solesence, Inc. Common StockSLSN
1.3×
Lifevantage Corporation logo
Lifevantage CorporationLFVN
0.3×-0.5×
Estee Lauder Companies Inc. logo
Estee Lauder Companies Inc.EL
2.1×+0.1×
NuSkin Enterprises logo
NuSkin EnterprisesNUS
0.3×0.0×
Kenvue logo
KenvueKVUE
2.7×-0.9×

Other financials

Income statement

See full
Revenue$64.9M-6.7%
Gross profit$44.4M-8.5%
Operating income-$1.8M+85.0%
Net income-$6.6M+34.3%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$204.4M-45.2%
Total debt$125.9M+756%
Total equity$55.2M+19.9%
Total assets$473.2M-29.8%

Cash flow

See full
Operating cash flow-$5.6M-285%
CapEx$224.0K+398%
Free cash flow-$5.8M-296%

Valuation

See full
Market cap$89.75M-61.5%
Enterprise value$11.24M-96.2%
P/S0.3×-0.4×

Profitability

See full
Gross margin64.9%+8.3pp
Operating margin-3.6%-1.6pp
Net margin-2%-0.9pp
FCF margin9.6%

Returns & leverage

See full
Return on equity-12%-5.4pp
Debt / equity2.3×+2.0×
Current ratio1.8×-5.7×

Where this comes from

Calculated from The Beauty Health Company’s reported figures.

Based on the most recent quarter.

The official record: The Beauty Health Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Beauty Health Company's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Beauty Health Company's EV / sales?
The Beauty Health Company (SKIN) reported EV / sales of 0.1× in Q1 2026.
How has The Beauty Health Company's EV / sales changed year-over-year?
The Beauty Health Company's EV / sales increased by 120.1% year-over-year, from -0.6× to 0.1×.
What is the long-term trend for The Beauty Health Company's EV / sales?
Over 4 years (2021 to 2025), The Beauty Health Company's EV / sales has grown at a -59.8% compound annual growth rate (CAGR), from 10.6× to 0.3×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.